<DOC>
	<DOCNO>NCT02969018</DOCNO>
	<brief_summary>The purpose study determine whether PF-06700841 safe effective treatment chronic plaque psoriasis .</brief_summary>
	<brief_title>Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have diagnosis plaque psoriasis ( psoriasis vulgaris ) least 6 month prior Baseline/Day 1 ( prior first dose study drug ) Have PASI score 12 great AND PGA score 3 ( `` moderate '' ) 4 ( `` severe '' ) Baseline/Day 1 ( prior first dose study drug ) Have plaquetype psoriasis cover least 10 % total body surface area ( BSA ) Baseline/Day 1 ( prior first dose study drug ) Considered dermatologist investigator candidate systemic therapy phototherapy psoriasis ( either na√Øve history previous treatment ) Currently nonplaque form psoriasis , eg , erythrodermic , guttate , pustular psoriasis , exception nail psoriasis allow Have evidence skin condition ( eg , eczema ) time screen baseline visit would interfere evaluation psoriasis Can discontinue systemic therapy and/or topical therapy treatment psoriasis discontinue phototherapy ( UVB PUVA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>plaque psoriasis</keyword>
</DOC>